| 1 |
Review Eyes on the prize: federal Alzheimer's research effort aims to facilitate interventions. 2008
Hodes RJ, Buckholtz N, Cahan V, Morrison-Bogorad M. · National Institute on Aging, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD, USA. · Alzheimers Dement. · Pubmed #18631998 No free full text.
Abstract: The public Alzheimer's disease (AD) research enterprise began in earnest in the mid-1970s with the creation by Congress of the National Institute on Aging at the National Institutes of Health. Today, AD research is a maturing field of study, with federal effort seeking to encourage the creativity and insights of individual investigators, and targeting special areas for emphasis. It is inspired by the legacy of our friend and colleague Leon Thal, whose innovative and collaborative approach to scientific research serves as a guidepost as we move toward the discovery of new and effective ways to prevent AD or slow its progression. This article describes the progress to date and potentially promising areas of study from the vantage point of the National Institute on Aging.
|
| 2 |
Review The future of aging therapies. 2005
Hadley EC, Lakatta EG, Morrison-Bogorad M, Warner HR, Hodes RJ. · National Institute on Aging, National Institutes of Health, Bethesda, Maryland 20892, USA. · Cell. · Pubmed #15734687 No free full text.
Abstract: Advances in understanding aging processes and their consequences are leading to the development of therapies to slow or reverse adverse changes formerly considered to be "normal" aging and processes that underlie multiple age-related conditions. Estimating the effectiveness of candidate aging therapies, whose effects on human aging may require many years to determine, is a particular challenge. Strategies for identifying candidate interventions can be developed through multiple approaches, including the screening of molecular targets and pathways in vitro and in animal models, informed as well by evidence from human genetic and epidemiologic data. A number of recently established programs and networks can serve as resources for such research. For all these research approaches, from in vitro molecular studies to clinical trials, contributions of cell and molecular biology are crucial and offer the prospect of therapeutic advances that address fundamental biological processes as well as the clinically important challenges of aging.
|
| 3 |
Article Public funding for Alzheimer disease research in the United States. 2006
Hodes RJ. · National Institute on Aging, National Institutes of Health, Room 5C35, 31 Center Drive, Bethesda, Maryland 20892, USA. · Nat Med. · Pubmed #16829943 No free full text.
This publication has no abstract.
|
| 4 |
Minor Consensus report of the Working Group on: molecular and biochemical markers of Alzheimer's disease. 1999
Thies B, Truschke E, Morrison-Bogorad M, Hodes RJ. · No affiliation provided · Neurobiol Aging. · Pubmed #10537034 No free full text.
This publication has no abstract.
|
|
|